SALKALLI- retatrutide lyophilized powder 10mg injection, powder, lyophilized, for solution

Guangzhou Yixin Cross-border E-commerce Co., Ltd.

Active ingredients (in each kit)

Retatrutide 10 mg (lyophilized powder)
Sterile Water for Injection 1 mL

Purpose

Antidiabetic / Weight management agent

Diluent

Uses

Helps control blood sugar in adults with type 2 diabetes (when prescribed). Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort. Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

 $10 \text{ mg} \div 1 \text{ mL} = 10 \text{ mg/mL}.$

Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

Weeks 1-4: 0.25 mL (2.5 mg) once weekly (subcutaneous)

Weeks 5-8: 0.5 mL (5 mg) once weekly

Weeks 9-12: 0.75 mL (7.5 mg) once weekly

Week 13 and onward: 1 mL (10 mg) once weekly

One carton (4 kits) provides 4 weekly doses.

How to prepare and inject (patient summary):

Wash hands with soap and water. Inspect vials for damage.

Using aseptic technique, withdraw the prescribed volume (in mL) of Sterile Water for Injection into a sterile syringe. Inject the diluent into the vial containing the lyophilized powder.

Gently swirl the vial until the powder fully dissolves. Do not shake vigorously. Solution should be clear; do not use if cloudy or particulate present.

Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol. Rotate injection sites.

Dispose of syringe/needle in an appropriate sharps container.

Do not use

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Co-

administration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

When using section

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

stop use

Pancreatitis: Cases of pancreatitis have been reported. If you have severe abdominal pain (that may spread to the back), persistent vomiting, or signs of pancreatitis — stop using and contact your healthcare provider immediately.

Allergic reaction: Serious allergic reactions have been reported. Stop use and seek emergency care if you have hives, swelling of face/lips/tongue/throat, or trouble breathing.

Serious gastrointestinal disease: May cause GI adverse reactions. Not recommended for patients with severe GI disease (not studied).

Acute gallbladder disease: Cases (e.g., gallstones) have been reported. If you experience severe right-upper-abdominal pain or jaundice, seek medical evaluation.

Hypoglycemia warning: Do not use RETATRUTIDE if you have a history of recurrent or severe hypoglycemia. RETATRUTIDE may further lower blood glucose levels. Use is contraindicated in individuals with baseline hypoglycemia or conditions predisposing to hypoglycemia.

Pregnancy or breastfeeding: Do not use.

Children: Do not use.

Drug Interactions / Precautions

Other antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or sulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely monitored; doses of other antidiabetic drugs may need adjustment.

Drugs affecting gastrointestinal motility: Retatrutide may delay gastric emptying. Coadministration with prokinetic agents (e.g., domperidone) or antacids may alter absorption or worsen GI discomfort.

Cardiovascular medications: Caution with statins, digoxin, or warfarin.

Statins: absorption may be affected; monitor lipid levels.

Warfarin: changes in metabolism may alter anticoagulant effects; monitor INR levels.

General precautions: Retatrutide should be used only under medical supervision. Inform your healthcare provider about all medications, including prescription, over-the-counter, and herbal products.

Possible side effects

Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.


Keep out of reach of children.

Not for use in children.

Inactive Ingredients:

Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.

PRINCIPAL DISPLAY PANEL





SUIKUIII

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits) 1ml: 10mg

1_{mL:}

Salkalli™ R



USA

Retatrutide (lyophilized powder)

1 set containing 2 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply) **10**mg



Each kit contains: Retatrutide 10 mg vial + Sterile Water for Injection 1 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Solitality

Company address line 1]

(Company address line 1]

(City, State, Country)

Customer Service: [phone] | [email] | [website]

Contents:

1 set containing 2 cartons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Retartutate 10 mg (hyophilized powder)
1 vial Retartutate 10 mg (hyophilized powder)
1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate of 2-8° ($^{\circ}$ 63-64 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use.

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale

1ml: 10mg

DRUG FACTS — For Patient Use (Prescription)

Active ingredients (in each kit)
Retatrutide 10 mg (lyophilized powder)
Sterile Water for Injection 1 mL

Purpose- Antidiabetic / Weight management agent
- Diluent

Uses

- Helps control blood sugar in adults with type 2 diabetes (when prescribed).
- Intended to assist adults with weight loss as directed by a healthcare provider.

Warnings — Read carefully and tell your doctor if any apply to you.

- Formandisco, color operations of the process of the

- Children: Do not use. **Drug Interactions / Precurtions**Other ontidiabetic medications. Retrotucide lowers blood glucose. Using it with insular or other ontidiabetic medications. Retrotucide lowers blood glucose. Using it with insular or other ontidiabetic dispressions. Blood glucose should be closely monitored, doses of other ontidiabetic drugs may need odjustment. **Drugs affecting sostrainestation laulity. Retrotucides my delay gastric emphigo.**Co-daminatrollon with problemic openis (e.g., domepaidoxe) or entocids may after absorption.
 Co-daminatrollon medications. Custom with statins, digastri, or varorin.
 O statiss absorption may be affected, monitor lipid levels.
 O Worldrin: Chappels in retroblemin may be affected, monitor lipid levels.
 O Worldrin: Chappels in retroblemin may be affected provider effects, monitor file levels.
 The provider of the provider o

Possible side effects

When to stop and call your doctor

• If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration after reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly dosing schedule (example shown — follow your prescriber):

• Weeks 1-4: 0.25 mL (25 mg) once weekly (subcutaneous)

- One cortion (4 kHz) provides a veelety doses.

 New to prepare not dinject (potient summary):

 1. Wosh hinneds with soop and water, inspect viols for domage,

 2. Wosh hinneds with soop and water. Inspect viols for domage,

 2. Wash provided to the state of the state

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.


Other information

- Store unused kits at tom temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C

97 °G and 68 °P) are permitted. After reconstitution, refrigerate at 2-8°C (164-46 °P) and use width 27 shours. Protect from kight and moistate. Do not feetac. Resp. in original continual use. Proceedings of the control o

10mg冻干减肥注射器-3件套封套 尺寸:200 x 127 x 122 mm

工艺:350g白卡过光膜,四色印



200mm

Salkalli™

Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits) 1ml: 10mg

Salkalli™

USA

Retatrutide (lyophilized powder)

1 set containing 3 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use Rx Only — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)



1_{mL:} **10**mg

Each kit contains: Retatrutide 10 mg vial + Sterile Water for Injection 1 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Manufactured for: Salkalli™

Salkalli**
[Company address line 1]
[City, State, Country]
Customer Service: [phone] | [email] | [website]

- Customer Service: [phone] [[email]] [website]
 Contents:
 1 set containing 3 caratons,
 each carato containing 4 complete single-use kits, each kit containing:
 -1 vial Retutrutide 10 mg (kyophilized powder)
 -1 vial Sterile kerter for injection 1 mL
 -1 sterile syringe

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (35-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

1ml: 10mg

DRUG FACTS — For Patient Use (Prescription)

Purpose Antidiabetic / Weight management agent Diluent

Uses

• Helps control blood sugar in adults with type 2 diabetes (when prescribed),
• Intended to assist adults with weight loss as directed by a healthcare proving

- Intended to assist adults with weight loss as directed by a healthcare provider.

 **Warnings Read carefully and tell your doctor if any apply to you.

 **Pantereutitis: Costs of panceutitis have been regarded. If you have severe addominal pain and contact your healthcare provider immediately.

 **Allergic reaction: Serious aftering reactions have been reported. Stop use and seek emergency core if you have hives, swelling of facellipstronguithroat, or touble breathing.

 **Serious gasterinetism diseases: May couse of any evers encircless. Not recommended for potients with severe of ideases (not studied).

 **Acting plittleded decisers: Costs les gr., guidateness have been recorted. If you experience.

 **Allergic reaction: Applications of the providers of the properties of the properties of the properties of the properties.

 **Prophylerinetis (RATRUIDIC for you factor have been a history of recurrent as severe the prophylerinetis. RATRUIDIC for you factor levels being discusse levels. Use is controllected in individuals with baseline hypophycemical controllected in Individuals with baseline hypophylerinetis. RATRUIDIC for you factor levels. Use is controllected in Individuals with baseline hypophycemical controllected in Individuals with baseline hypophylerinetis. Ratruid in Individuals with baseline hypophylerinetis. Ratruid in Individuals with baseline hypophylerinetis. Ratruid Individuals with baseline hypophylerinetis. Ratruid Individuals with baseline hypophylerinetis. Ratruid Individuals with baseline hypophylerinetis.

- **Chaldern to not use.

 Dray Interaction Precurition**

 **Other antidabetic medications Retarratise lowers blood glucose. Using it with insulin or authorized the medications retards the property of the state o

Possible side effects Nousen disease

When to stop and call your doctor

If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, jaundice, or other serious symptoms.

Directions — Preparation & Dosing (basic patient summary)

Concentration ofter reconstitution (calculation):

• 10 mg + 1 mL = 10 mg/mL.

• Therefore: 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.

Typical weekly (soling schedul: (grouple shown — follow your prescriber): Weekles 1-40. Dis Carl goal goes exceedity Weekles 5-6. Dis Mill (Simg) lone weekly One carroin (4 kill provides 4 weekly) doese.

- New York was go violent ** weekly violent **.

 **New to praper and inject (patient summary):

 1. Wosh hinds with soop and water. Inspect viole for damage.

 2. Using agestic textural, withdraw the prescribed volume (in mit,) of Sterile Water for Injection attors a self-in syringer. Bytec the observed in the wist containing the yophildrad provider. All to a self-in syringer self-in the observed in the self-in syringer self-in se

Inactive Ingredients:
Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride,
Sodium Bicarbonate.

Other information

Store unseed sits or come temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C
(5°F ° and 56°F) are permitted. After reconstitution, refrigerate at 2-6°C (5-4-6°F) and use
(50°F) and 56°F) are permitted. After reconstitution, refrigerate at 2-6°C (5-4-6°F) and use
(50°F) are in the single-use. Discard any unused solution.

Keep out of reconstrict of children.

For questions, contact. Solution! Customer Care: [phone / email / website – insert). To report
side effects, cally our healthcase provider.

10mg冻干减肥注射器-4件套封套 尺寸:200 x 127 x 162 mm 工艺:350g白卡过光膜,四色印



200mm

Salkalli™

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

1ml: 10mg

1_{mL}:

10_{mg}

Salkalli[™] ^R_x

USA

Retatrutide (lyophilized powder)

1 set containing 4 cartons (each carton contains 4 kits)

For Reconstitution and Subcutaneous Use Only — Not for IV use **Rx Only** — Dispense only with prescription

Each kit provides a single weekly dose. One carton provides 4 weekly doses(4-week supply)



Each kit contains: Retatrutide 10 mg vial + Sterile Water for Injection 1 mL vial + sterile syringe

Store at room temperature below 25 °C (77 °F) before reconstitution. Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After mixing, refrigerate at 2–8 °C (36–46 °F) and use within 24 hours per vial.

See enclosed leaflet for full instructions.



Manufactured for:
Salkalli"
[Company address line 1]
[City, State, Country]
Customer Service: [plone] 1 [email] 1 [website]
Contents:
1 set containing 4 cartons,
each corton containing 4 complete single-use kits, each kit containing:
1 vial Retarturation 10 mg (hyohilized powder)
1 vial Sterile Water for injection 1 mL.
1 sterile symrage

Storage: Store unused kits at room temperature below 25 °C (77 °F). Excursions between 15 °C and 30 °C (59 °F and 86 °F) are permitted. After reconstitution, refrigerate at 2-8 °C (36-46 °F) and use within 24 hours. Protect from light and moisture. Do not freeze. Keep in original corton until use

NDC: 00000-000-00. Rx Only. For prescription use only. Not for sale without prescription.

1ml: 10mg

RUG FACTS — For Patient Use (Prescription)	Possible side effects Nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia (indigestion), abdominal pain. If side effects are severe or persistent, contact your healthcare provider.		
tive ingredients (in each kit) Purpose atrutide 10 ma (hvochilized powder) Antidiobetic / Weight management goent	When to stop and call your doctor If you develop severe abdominal pain (possible pancreatitis), severe allergic reaction, joundice, or other serious symptoms.		
rile Water for Injection 1 mL Diluent	Directions — Preparation & Dosing (basic patient summary)		
es elps control blood sugar in adults with type 2 diabetes (when prescribed). tended to assist adults with weight loss as directed by a healthcore provider,	Concentration after reconstitution (calculation): 10 mg + 1 mL = 10 mg/mL. Thereforce 0.25 mL = 2.5 mg; 0.5 mL = 5 mg; 0.75 mL = 7.5 mg; 1 mL = 10 mg.		
ranings — Read carefully and tell yeur dector if any apply to you. ancreatilist. Cance of promoreatilis how been reported if you byce severe abdomined pain but may spread to the book), persistent verniting, or signs of pencreatilist — stop using and notant your beathering provider immediately expenses the provider time declared, lellergic recotions serious allergic recotions have been resported. Stop use and seek emergency are if you have helves, swelling of focalishipsingswithrough extra better betterhing.	Typical weekly dusting schedule (scample shown — follow your prescriber): Venich + 0.5 mC II. 7 mill prose weekly (subcutamous) *Weeks + 6.0 5.m (K. mill prose weekly *Weeks + 7.0 0.7 m (T. mill prose weekly) *Week + 7.0 0.7 m (T. 7 mill prose weekly) *Week + 10 mill prosecution (H. Mill provides weekly) One carrior (A filts) provides weekly doses.		
erious gastrointestinal diseases. May cause of adverse reactions. Not recommended for translations with several diseases prior studies of the several properties. If you experience the several properties of the several properties of the several properties of the several properties which the several properties of the several pr	Herr to propers and fuject (partient summary): 1. With home with boung ord worker hospect viola for damage. 2. Using caspic behaviour, which was the prescribed volume (in nt.) of Starie Water for Injection into a starie syrings, light of Mueller Into the Volume (in nt.) of Starie Water for Injection into a starie syrings, light of Mueller Into the Volume (in nt.) of Starie Water for Injection into a Starie Water for Injection into a Starie Water for Injection of Staries Water for Injection should. 4. Withdraw the prescribed volume (e.g. 0.25, 6.5, 5.7 or 1m) know staries variege and inject subcutoneously in the obdomen, thigh, or upper orm after cleaning the site with alcohol. Staties registerion size.		
ug Interactions / Precautions ther antidiabetic medications: Retatrutide lowers blood glucose. Using it with insulin or ulfonylureas may increase the risk of hypoglycemia. Blood glucose should be closely onaticed; doses of other antidiabetic drugs may need adjustment. urgs affecting agarointestional malility. Retatrutide may delay gastric emptying.	Inactive Ingredients: Mannitol, Disodium Hydrogen Phosphate, Sodium Dihydrogen Phosphate, Sodium Chloride, Sodium Bicarbonate.		
odaministration with prokinetic agents (e.g., domperations) or amacists may after absorption versers of disconfired research agents (e.g., domperations) or war forin. ordioversacial medications called the states, disposing or war forin. Ordioversacial medications are states, and the states of	Other information • Store unsade kins in room temperature below 25 °C (77 °P). Excursions between 15 °C and 30 °C (59 °P and 36 °P) are permitted. After reconstitution, refrigerate at 2 °C 15 °C 15 °C 15 °C and 30 °C (59 °C 150 °C) and 150 °C (50 °C) are permitted. After reconstitution, refrigerate at 2 °C 15		

SALKALLI

retatrutide lyophilized powder 10mg injection, powder, lyophilized, for solution

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:84778-115
Route of Administration	SUBCUTANEOUS		

Active Ingredient/Active Moiety			
Ingredient Name	Basis of Strength	Strength	
RETATRUTIDE (UNII: NOP2Y096GV) (RETATRUTIDE - UNII:NOP2Y096GV)	RETATRUTIDE	10 mg in 1 mL	

Inactive Ingredients			
Ingredient Name	Strength		
SODIUM BICARBONATE (UNII: 8MDF5V39QO)			
MANNITOL (UNII: 30WL53L36A)			
SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)			
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)			

SODIUM CHLORIDE (UNII: 451W47IQ8X)

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:84778-115- 02	2 in 1 PACKAGE, COMBINATION	10/30/2025	
1		4 in 1 CARTON		
1		1 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
2	NDC:84778-115- 01	4 in 1 CARTON	10/30/2025	
2		1 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
3	NDC:84778-115- 03	3 in 1 PACKAGE, COMBINATION	10/30/2025	
3		4 in 1 CARTON		
3		1 mL in 1 KIT; Type 1: Convenience Kit of Co-Package		
4	NDC:84778-115- 04	4 in 1 PACKAGE, COMBINATION	10/30/2025	
4		4 in 1 CARTON		
4		1 mL in 1 KIT; Type 1: Convenience Kit of Co- Package		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
Export only		10/30/2025	

Labeler - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Registrant - Guangzhou Yixin Cross-border E-commerce Co., Ltd. (455800881)

Establishment				
Name	Address	ID/FEI	Business Operations	
Guangzhou Yixin Cross-border E-commerce Co., Ltd.		455800881	label(84778-115) , manufacture(84778- 115)	

Revised: 11/2025 Guangzhou Yixin Cross-border E-commerce Co., Ltd.